Home・Listă Acțiuni・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Închisă

SectorSănătate

38.21 -1.39

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

38.21

Maxim

39.09

Indicatori cheie
By Trading Economics
Venit	10M 32M
Vânzări	-28M 215M
P/E Medie Sector	14.355 68.51
EPS	0.79
Marjă de profit	15.084
Angajați	293
EBITDA	-2.8M 49M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	+8.38% upside

Dividende
By Acuity
Următoarele câștiguri	3 nov. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	175M 2.1B
Deschiderea anterioară	39.6
Închiderea anterioară	38.21

Sentimentul știrilor

By Acuity

25%

75%

59 / 340 Clasament în Healthcare

Harmony Biosciences Holdings Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

7 aug. 2026, 20:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower amid broader market declines and decreasing Treasury yields following recent economic data.

6 aug. 2026, 23:51 UTC

Harmony Biosciences Holdings Inc shares declined during after-market hours, struggling to maintain earlier gains amid a lack of specific news to explain the movement.

5 aug. 2026, 20:03 UTC

Social Media

Event

News

Harmony Biosciences shares are lower despite new Phase 1 data on BP-205. Truist maintains a Hold rating and raises the price target to $34.

4 aug. 2026, 20:04 UTC

Social Media

News

Event

Harmony Biosciences reported strong Q2 earnings of $75.43 million and reaffirmed 2026 revenue guidance, with shares trading sharply higher during the session.

3 aug. 2026, 23:11 UTC

Harmony Biosciences shares are higher in after-hours trading, supported by positive sentiment from the Institute for Supply Management's manufacturing PMI report.

1 aug. 2026, 00:01 UTC

Shares of Harmony Biosciences Holdings Inc are higher in after-market trading, reflecting notable strength since Friday's close without any specific news driving the move.

31 iul. 2026, 23:21 UTC

Harmony Biosciences Holdings Inc. is trading higher during after-market hours, reflecting steady price increases since Friday's close, despite no specific news identified.

28 iul. 2026, 18:26 UTC

News

Shares of Harmony Biosciences are lower despite a 30% revenue increase for WAKIX, as market sentiment reflects concerns over potential cash flow erosion.

27 iul. 2026, 19:41 UTC

Shares of Harmony Biosciences Holdings Inc. are higher today, breaking from a recent upward trend despite the absence of specific company news.

24 iul. 2026, 17:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower today, continuing a decline since Thursday's close, despite earlier reaching a session high.

22 iul. 2026, 20:01 UTC

News

Harmony Biosciences Holdings Inc is trading lower despite preliminary Q2 2026 results showing record net product revenue of approximately $261 million, a 30% year-over-year increase.

21 iul. 2026, 21:01 UTC

Harmony Biosciences Holdings Inc. shares are lower in after-market trading, diverging from a broader market rebound despite no specific news driving the decline.

Comparație

Modificare preț

Harmony Biosciences Holdings Inc Așteptări

Obiectiv de preț

By TipRanks

8.38% sus

Prognoză pe 12 luni

Medie 41.63 USD 8.38%

Maxim 55 USD

Minim 30 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHarmony Biosciences Holdings Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

8 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 8 analiști care au acordat evaluări ale acțiunilor Harmony Biosciences Holdings Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

59 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.